Next Article in Journal
A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19
Next Article in Special Issue
Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing
Previous Article in Journal
Special Issue “Transmission Dynamics of Insect Viruses”
Previous Article in Special Issue
Development and Application of Performance Assessment Criteria for Next-Generation Sequencing-Based HIV Drug Resistance Assays
Review

Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework

1
National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3L5, Canada
2
Scientific Informatics Services at National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
3
Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium
4
Center for Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universida de Nova de Lisboa, 1349-008 Lisbon, Portugal
5
Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
6
AIDS Reference Laboratory, University Hospital Leuven, 3000 Leuven, Belgium
*
Author to whom correspondence should be addressed.
Received: 13 May 2020 / Revised: 29 May 2020 / Accepted: 11 June 2020 / Published: 14 June 2020
(This article belongs to the Special Issue Next Generation Sequencing for HIV Drug Resistance Testing)
Next-generation sequencing (NGS) in HIV drug resistance (HIVDR) testing has the potential to improve both clinical and public health settings, however it challenges the normal operations of quality management systems to be more flexible due to its complexity, massive data generation, and rapidly evolving protocols. While guidelines for quality management in NGS data have previously been outlined, little guidance has been implemented for NGS-based HIVDR testing. This document summarizes quality control procedures for NGS-based HIVDR testing laboratories using a laboratory information systems (LIS) framework. Here, we focus in particular on the quality control measures applied on the final sequencing product aligned with the recommendations from the World Health Organization HIV Drug Resistance Laboratory Network. View Full-Text
Keywords: laboratory information systems; HIV-1 drug resistance; next-generation sequencing; quality control; quality management laboratory information systems; HIV-1 drug resistance; next-generation sequencing; quality control; quality management
Show Figures

Figure 1

MDPI and ACS Style

Capina, R.; Li, K.; Kearney, L.; Vandamme, A.-M.; Harrigan, P.R.; Van Laethem, K. Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework. Viruses 2020, 12, 645. https://0-doi-org.brum.beds.ac.uk/10.3390/v12060645

AMA Style

Capina R, Li K, Kearney L, Vandamme A-M, Harrigan PR, Van Laethem K. Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework. Viruses. 2020; 12(6):645. https://0-doi-org.brum.beds.ac.uk/10.3390/v12060645

Chicago/Turabian Style

Capina, Rupert, Katherine Li, Levon Kearney, Anne-Mieke Vandamme, P. R. Harrigan, and Kristel Van Laethem. 2020. "Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework" Viruses 12, no. 6: 645. https://0-doi-org.brum.beds.ac.uk/10.3390/v12060645

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop